tbuckley/cabot-search huggingface dataset:
Abstract 12158: Higher Body Mass Index is Associated With More Heart Failure-Related Hospitalizations in Patients With Heart Failure With Preserved Ejection Fraction
Authors: Camilla Schmidt Morgen, Christiane L Haase, Tugce Kalayci Oral, Volker Schnecke, Anette Varbo, Barry A Borlaug
Journal: Circulation (2021)

Introduction: In people with heart failure (HF) with preserved ejection fraction (HFpEF), the associations between BMI, comorbidities and outcomes are not well-defined. This retrospective cohort study examined the association between BMI and hospitalizations in patients with HFpEF. Hypothesis: Higher BMI is associated with more HF-related hospitalizations and shorter time to HF-related hospitalization. Methods: Data for patients with BMI ≥25 kg/m 2 at the time of HFpEF diagnosis were extracted from LCED, a US claims-electronic medical record data set. Patients were categorized into 5 BMI groups: overweight and obesity classes I-IV (Figure A). Negative binomial and Cox proportional hazard models were used to estimate associations between BMI and number of HF-related hospitalizations and risk of HF-related hospitalization during follow-up. Analyses were adjusted for relevant baseline comorbidities, with age, sex and diabetes status as effect modifiers. Results: Among 4,975 patients, median age was 74 years and 57.5% were female. Compared with the overweight group, higher BMI groups had a lower median age (years: overweight 80; obesity III 68; obesity IV 64), fewer patients with cardiovascular (CV) history (overweight 81.0%; obesity III 77.0%; obesity IV 66.0%) and a greater proportion of female patients (overweight 56.4%; obesity III 57.9%; obesity IV 69.0%) (Figure A). Mean HF-related hospitalizations/100 patient-years was higher for obesity III (12) and IV (16) vs overweight (10) (effect of BMI: p=0.002; Figure B). The hazard ratio [95% CI] for HF-related hospitalization was 1.36 [0.97; 1.91] and 1.86 [1.32; 2.64] for obesity III and IV, relative to overweight (effect of BMI: p=0.010). Conclusions: Results suggest even though patients with HFpEF in higher BMI groups are younger and have less CV history at baseline, higher BMI is associated with greater burden of HF-related hospitalizations during follow-up, irrespective of age, sex and diabetes status.
TAMI-29. MR SPECTROSCOPY MEASURES OF LAC/NAA AND NAA/CHO DIFFERENTIATE SURVIVORSHIP IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH ANTI-ANGIOGENIC THERAPY
Authors: Pratik Talati, Mohamed El-Abtah, Daniel Kim, Jorg Dietrich, Melanie Fu, Michael Wenke, Julian He, Sharif Natheir, Mark Vangel, Otto Rapalino, Anna Vaynrub, Isabel Arrillaga-Romany, Deborah Forst, Yi-Fen Yen, Ovidiu Andronesi, Jayashree Kalpathy-Cramer, Bruce Rosen, Tracy Batchelor, Ramon Gonzalez, Elizabeth Gerstner, Eva-Maria Ratai
Journal: Neuro-Oncology (2021)

Abstract Patients with recurrent glioblastoma (rGBM) are often started on anti-angiogenic therapy such as bevacizumab. However, determining treatment failure using conventional MRI methods remains challenging. We prospectively collected longitudinal MR spectroscopy data in 33 patients with rGBM and quantified various metabolites including N-acetylaspartate (NAA), Choline (Cho), and Lactate (Lac). After stratifying patients by 9 month survival, we found that longer-term survivors had decreased Lac/NAA and increased NAA/Cho compared to shorter-term survivors. ROC analyses illustrated that intratumoral changes in NAA/Cho were predictive of survival at 1 day (AUC 0.92), 2 weeks (AUC 0.75), 8 weeks (AUC 0.71) and 16 weeks (AUC 0.85) but not 4 weeks (AUC 0.60). Intratumoral changes in Lac/NAA were predictive of survival at all time points tested (AUCs &amp;gt; 0.76 for all time points). At 8 weeks, 90% of patients with increased Lac/NAA from baseline and 88% of patients with decreased NAA/Cho did not survive 9 months. Changes in NAA/Cho and Lac/NAA may serve as early biomarkers of anti-angiogenic treatment failure.
Abstract 11143: Efficacy and Safety of Inclisiran by Baseline Body Mass Index: A Post Hoc Pooled Analysis of the ORION-9, ORION-10 and ORION-11 Phase III Randomized Controlled Trials
Authors: Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Kausik K Ray, Gregory G Schwartz, R S Wright, yanntong chiang, Lorena Garcia Conde Orozco, Frederick J Raal
Journal: Circulation (2021)

Introduction: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent with twice-yearly subcutaneous dosing (after the initial and 3-month doses). Aim: To analyze the efficacy and safety of inclisiran in patients with heterozygous familial hypercholesterolemia, atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent across body mass index (BMI) strata. Methods: In this post hoc analysis from ORION-9 (NCT03397121), ORION-10 (NCT03399370) and ORION-11 (NCT03400800), eligible patients were randomized 1:1 to receive 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) or placebo at baseline, Day 90 and 6-monthly thereafter. Analyses were stratified by baseline BMI: &lt;25, 25-&lt;30, 30-&lt;35 or ≥35 kg/m 2 . Percentage change in atherogenic lipids from baseline at Day 510 was evaluated. Safety was assessed over 540 days. Results: Baseline demographic and clinical characteristics including atherogenic lipid levels were mostly balanced between the treatment arms and across the BMI strata ( Table ). Percentage change in atherogenic lipids from baseline at Day 510 was significantly greater with inclisiran vs placebo within each BMI stratum ( Table ). Treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events were generally similar between the treatment arms and were reported more frequently with increasing BMI strata (data not shown). Clinically relevant TEAEs at the injection site were reported more frequently with inclisiran vs placebo similarly across strata, but all were mild or moderate. Conclusions: Twice-yearly dosing with inclisiran (after the initial and 3-month doses) provided effective and sustained lipid lowering in patients, irrespective of their baseline BMI, and was generally well tolerated.
Effect of 7 vs 14 Days of Antibiotics Among Afebrile Men With Urinary Tract Infection
Authors: Haroon Ahmed, David Gillespie, Emma Thomas-Jones
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prioritizing Prevention of Teen Dating Violence
Authors: Maya Ragavan, Elizabeth Miller
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 11926: Angiotensin-(1-7)/mas Receptor Agonist Protects Hippocampus Neurons In Mouse Model Of Vascular Dementia
Authors: Christina H Hoyer-kimura, John P Konhilas, Heidi Mansour, Robin L Polt, Meredith Hay
Journal: Circulation (2021)

Decreased brain blood flow, increased inflammation, and increased reactive oxidative species (ROS) are correlated to accelerated progression of both vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer's disease related dementia (ADRD). It has been previously demonstrated that VCID models with blood brain barrier dysfunction exhibit hippocampal neuronal loss and impaired cognitive function. Our novel synthetic glycosylated Angiotensin-(1-7) derivative (PNA5), has an enhanced half-life and is optimized for better blood-brain-barrier penetration. In our preclinical VCID model, PNA5 treatment inhibits brain ROS production, and reverses cognitive deficits. We hypothesized that 1) neuronal cell count in the CA1 region of the hippocampus will be decreased in our heart failure (HF) induced VCID mouse model and 2) PNA5 treatment will mitigate neuronal cell loss within the hippocampus and protect cognitive function. VCID was induced in adult male C57BL/6J mice (10-15/group), via HF. Control mice underwent sham surgery. Following 5 weeks post coronary ligation, mice were treated with either 1) saline or 2) 50 micrograms/kg/day PNA5, via daily subcutaneous injection for 21 days. Novel-object recognition was used to measure cognitive function and is represented as a DRatio. VCID-Saline mice displayed cognitive impairment (DRatio mean -0.02, SE + 0.07) compared to Control-Saline (DRatio 0.57 + 0.1). Cognitive function was rescued by PNA5 treatment (DRatio 50micrograms/kg/day 0.61 + 0.09). Hippocampal neuronal cell loss was determined through analysis of free-floating formalin fixed 16micron cryosection brains, stained with NeuN (ab177487, 1:500) and counted using ImageJ. CA1 Hippocampal regions (-1.6 to -2.0 millimeters from bregma) were imaged at 40x magnification. Data were analyzed by one-way ANOVA. VCID-Saline mice displayed a significant decrease in neurons in the CA1 region (3.35 + 0.11 cell/ pixel linear area) compared to Control-Saline mice (3.94 + 0.12). Mice treated with PNA5 had significantly higher CA1 neuronal cell count (3.87 + 0.17) in comparison to VCID-Saline treated mice. These data suggest that PNA5 protects against VCID cognitive impairment and prevents neuronal cell loss in VCID mouse models.
Abstract 11076: Cardiac AKAP12 Overexpression Reduces Cyclic Amp Accumulation in the Vicinity of β2Ar
Authors: Hanan Qasim, Arfaxad Reyes Alcaraz, Bradley K McConnell
Journal: Circulation (2021)

Introduction: In Heart Failure (HF), signaling downstream the β2-Adrenergic Receptor (β2AR) is critical. Sympathetic stimulation of β2AR triggers Protein Kinase A (PKA) dependent phosphorylation of...
Abstract 12659: Associations Between Patient Demographic Characteristics and Odds of Repeat Ablation for Atrial Fibrillation
Authors: Brittany N Taylor, David J Slotwiner, Yelitza Castanos, Monica L Wilson, Meghan Reading Turchioe
Journal: Circulation (2021)

Introduction: Atrial fibrillation (AF) affects over 3 million adults in the United States and has an estimated direct healthcare cost of $6 billion. Between 2000 and 2013, there was an eightfold increase in the number of ablations for AF performed. However, success rates vary from 35%-80%. Because AF recurrence is common, patients may require repeat ablations, but less is known about which patients are at high risk for repeat ablations. The objective of this study was to investigate the prevalence of repeat ablations by patient demographic characteristics. Methods: From electronic health records, we identified all patients with an admitting diagnosis of paroxysmal AF using International Classification of Diseases billing codes who were treated at NewYork-Presbyterian Hospital from 2010 through 2019. We then identified patients who underwent ablation at the institution using Current Procedural Terminology codes and extracted ablation dates, age at first ablation, gender, race, and ethnicity. We summarized patient characteristics using standard descriptive statistics and evaluated associations between demographics and repeat ablations using logistic regression modeling. Results: Of the 1,799 patients studied, 31.0% were female, 54.0% were white, 4.0% were Hispanic or Latino, and 17.9% had at least one repeat ablation. At the first ablation, 19.7% of patients were under age 55, 26.4% aged 55 to 64, 33.4% aged 65 to 74, 16.3% aged 75-84, and 4.2% aged 85 and older. Subjects aged &lt;55 were significantly more likely to undergo repeat ablation compared to ( &gt; 85 (OR 2.03 [95% CI 1.01-4.54]). The odds of repeat ablation did not significantly differ by gender, race, or ethnicity. Conclusion: Younger age is associated with increased odds of repeat ablations. Age and other potential predictors of repeat ablations should be further studied in larger, more diverse samples controlling for relevant covariates.
Final Results of CHRONOS19 Observational Study in Patients with Hematologic Disease and COVID-19 in Russia
Authors: Olga A. Gavrilina, Kristina A. Zakurdaeva, Anastasia N. Vasileva, Sergei Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Lubov Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksander A. Siniaev, Kamil Kaplanov, Andrei Petrenko, Oksana Ochirova, Ekaterina Yu. Chelysheva, Yulia Sveshnikova, Vasily Shuvaev, Maria E. Grishunina, Julia A. Chabaeva, Alina Karpova, Alena Sukhareva, Dasha Baryshnikova, Tatiana V. Gaponova, Vera V. Troitskaya, Valery G. Savchenko
Journal: Blood (2021)
導入-強化化学療法におけるミトキサントロン対ダウノルビシン-寛解維持のための低用量シタラビンの有用性、及び高齢者における急性骨髄性白血病の予後因子の評価:オランダ-ベルギー血液腫瘍学共同Hovonグループ無作為化第III相試験AML-9及び欧州癌研究治療機関の白血病共同グループの最終報告
Authors: Loewenberg B, Suciu S, Haak H, Thyss A, Visani G, Fillet G, Hayat M, Solbu G, Zittoun R
Journal: Journal of Clinical Oncology (1998)
Abstract 12178: Photon Counting Computed Tomography for Aortic Valve Calcium Scoring in Contrast- Enhanced Datasets of the Heart
Authors: Eva K Harmel, Franziska Braun, Katharina Rippel, Christian Scheurig-Münkler, Thomas Kroencke, Evaldas Girdauskas, Wolfgang von Scheidt, Florian Schwarz
Journal: Circulation (2021)

Introduction: The prognostic value of aortic valve calcium in patients prior to TAVR is well established. Its reliable quantification requires a non-contrast CT of the heart (‘true non contrast’, TNC) which in this cohort is not regularly performed at all centers. Photon Counting Detector CT (PCD-CT) permits the routine derivation of ‘virtual non-contrast’ (VNC) series from CT Angiography (CTA) acquisitions due to its intrinsic spectral sensitivity. These might render separate non-contrast acquisitions unnecessary. The aim of our study was to evaluate the feasibility of aortic valve calcium quantification on VNC series derived from CTA scans. Methods: All patients underwent TAVR planning CT on a novel PCD-CT (NAEOTOM Alpha, Siemens Healthineers, Erlangen, Germany) comprising a non-contrast CT of the heart, followed by a CTA of the heart, aorta and iliac arteries. VNC series were derived from CTA acquisitions and two readers independently quantified aortic valve calcium scores and volumes on VNC- and TNC-series. Results: Here, we report initial results of the first 5 of 100 patients. In comparison with those derived from TNC series, calcium scores and volumes derived from VNC series were consistently lower (mean 713 vs. 1110 and 563 vs. 894 mm 3 ) but correlation was excellent for both calcium score and volume (r’s: 0.945 and 0.938, respectively, both p’s=0.01). Conclusions: Our initial patient experience with TAVR planning CT on a novel PCD-CT shows excellent correlation of aortic valve calcium scores and volumes derived from VNC series, as compared with those derived from TNC series. These will most likely be interchangeable, thus rendering non-contrast acquisitions redundant for TAVR planning. Figure 1 Corresponding series of a TAVR patient with high-grade aortic stenosis demonstrating severe aortic valve calcifications on (A) true non-contrast CT (TNT-Score: 3772), (B) CTA for annulus measurement and (C) VNC-reconstructions derived from CTA (VNC-Score: 3099).
TAMI-03. PROGNOSTIC SIGNIFICANCE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH BRAIN METASTASES FROM DIFFERENT TUMOR ORIGINS
Authors: Guanhua Deng, Lei Wen, zhaoming Zhou, Changguo Shan, Mingyao Lai, Cheng Zhou, Linbo Cai
Journal: Neuro-Oncology (2021)

Abstract PURPOSE Brain metastases (BMs) represent the most common adult intracranial malignancy. The prognosis of BMs is subject to many factors, i.e., the number, size and locations of the metastatic sites, tumor origins, pathologic types, gene mutation status, metastatic sites, and KPS etc. This study aimed to evaluate the prognostic value of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in brain metastases. METHODS A total of 480 patients diagnosed with brain metastases from a wide range of tumor origins, i.e., NSCLC, SCLC, breast cancer, melanoma, prostate, kidney, gastrointestinal cancer, cervical carcinoma, ovarian cancer, choriocarcinoma of uterus were retrospectively analyzed. Pre-radiotherapy NLR, PLR, and LMR were calculated as total neutrophil/lymphocyte, platelet/Lymphocyte, lymphocyte/monocyte, respectively. Survival rates were estimated using the Kaplan-Meier survival analysis. Cox regression models were used to identify independent prognostic factors. RESULTS The median overall survival (OS) was 14.4 months [95%CI: 13.4-15.5]. The median overall survival after radiotherapy was significantly different between patients with NLR&amp;lt; 4 and those with NLR≥4 (OS 16.3 mo. vs. 12.2 mo., P&amp;lt; 0.0001). No signiﬁcant difference was observed between PLR vs. OS, and LMR vs. OS (PLR&amp;lt; 180: HR=1.221, P=0.240; LMR&amp;lt; 4: HR=0.753, P=0.141). The Cox regression model for the continuous metric values revealed that the NLR increased every 1.0 was associated with additional 5.9% of fatal risk (HR: 1.059; 95%CI = 1.033–1.087, P&amp;lt; 0.0001). NLR was validated as an independent prognostic factor for risk of death after adjusting for sex, age, and KPS. CONCLUSIONS We revealed pre-treatment NLR is an independent prognostic factor in patients with brain metastases for poor OS, independent of different tumor origins. The NLR warrants further studies using sub-group analysis and validation in external cohorts. Future studies in this parameter have a potential to facilitate more precise risk-stratifications to guide personalized treatment for BM.
Abstract 9983: Thiamine Deficiency is Associated with Longer Length of Stay and Higher Hospitalization Cost in Patients with Atrial Fibrillation
Authors: Daniel Antwi-Amoabeng, Abdul-aziz Shittou, Mark Ulanja, Bryce Beutler, Joban Ghuman, Jasmine Ghuman, David T. Gbadebo
Journal: Circulation (2021)

Introduction: Chronic thiamine deficiency (TD) can cause changes in the myocardium through cellular hypotrophy, which may lead to arrhythmias. Although animal models have not revealed major electrical remodeling, supraventricular tachyarrhythmias are associated with low thiamine levels. TD is associated with chronic alcohol and loop diuretic use. The prevalence of TD in patients with supraventricular arrhythmias is unknown. We assessed the prevalence of TD among patients hospitalized for atrial fibrillation (AF) using data from the National Inpatient Sample (NIS) database between 2005 to 2015. Hypothesis: TD is prevalent in individuals with a history of chronic alcohol use and is associated with worse in-hospital outcomes. Methods: Using ICD-9 codes, we queried the NIS for discharge encounters involving adults with AF. We compared the differences in baseline characteristics and in-hospital outcomes between those with and without a diagnosis of TD using the Chi-Square test and the Wilcoxon rank-sum test as two-tailed at a 5% level of significance. Results: Of the 38,283,200 discharge encounters, 0.02% had a diagnosis of thiamine deficiency (N = 7,287). TD was common among white males, younger patients, and those with a history of chronic alcohol use. TD did not affect inpatient mortality but was associated with a longer hospital stay and a higher cost of care (Table 1). Conclusions: Among hospitalized patients with AF, TD does not affect in-hospital mortality but is associated with increased length of stay and cost of care. Further investigation is necessary to assess the effect of thiamine supplementation on AF burden and response to rate or rhythm control.
Abstract 13207: Peripartum Cardiomyopathy Clinical Characteristics and In Hospital Mortality: Insights From the National Impatient Sample
Authors: Gaspar Del Rio-Pertuz, Juan Daniel Del Cid Fratti, Cristina Morataya, Erwin E Argueta-Sosa
Journal: Circulation (2021)

Introduction: The epidemiology of peripartum cardiomyopathy (PPCM) has been described in various countries, with different outcomes and incidence depending on the race and location studied. Recent reports are limited by small sample sizes, which are not enough to make significant conclusions. The aim of the present study is to use a nationally representative database to evaluate clinical characteristics of patients with PPCM and to compare their intrahospital mortality. Hypothesis: We hypothesize that there are no significant racial disparities in hospital mortality in patients with PPCM. Methods: Retrospective analysis of the National Inpatient Sample (NIS) from 2016 to 2018. Patients with PPCM were identified using ICD10 codes and were classified by race (White, African American, Hispanic, Asian, Native American, and other race). The primary outcome was intrahospital mortality. A multivariate regression analysis was constructed to adjust for confounders. Results: We identified a total of 9,370 patients with PPCM. Of them, 36.4% were classified as White, 42.4% as African American, 10.8% as Hispanic, 3.31% as Asian, 1.01% as Native American, and 2.83% as other race. Diabetes was more common in Native Americans, in comparison with arterial hypertension and chronic kidney disease, which were more common in African Americans (Table 1). Compared to White race, the odds of intrahospital mortality in Asian, Hispanic and African American, did not differ amongst races (Figure 1). Conclusion: African Americans continue to have more prevalence of PPCM compared to other races. In this sample, intrahospital mortality did not differ. More studies are needed to evaluate if racial disparities contribute for the observed differences in PPCM prevalence and long term outcomes.